Strengthening the EU's
pandemic preparedness
ABOUT EVAMOBS
A novel platform to develop antivirals
EvaMobs is taking a new approach in antiviral development, by using evolvable monobodies, or “Mobs” for short.
Mobs are small proteins that can be tailored to have a high affinity for any type of virus. In other words, by making specific changes to the framework of Mobs, this technology can be used to easily generate specific molecules that can “attack” and inactivate a particular virus.
Using evolvable and rapidly adaptable Mobs in combination with computational tools, EvaMobs is creating an innovative platform for the rapid development of new antiviral drugs.
A monobody (in pink) tightly bound to the
SARS-COV-2 receptor binding domain (in blue)
ABOUT EVAMOBS
Our research steps
Discovery of new
Mobs
With a computational framework, millions of computer-designed Mobs will be discovered, and characterised.
Production of
specific Mobs
A narrowed down selection of discovered Mobs will be produced.
Preclinical
validation
The Mobs will undergo testing of the safety, efficacy and the dosage in preclinical models.
Phase 1 clinical
validation
The most promising Mob will be tested for safe use in humans.
Discovery of
new Mobs
With a computational framework, millions of computer-designed Mobs will be discovered, and characterised.
Production of
specific Mobs
A narrowed down selection of discovered Mobs will be produced.
Preclinical
validation
The Mobs will undergo testing of the safety, efficacy and the dosage in preclinical models.
Phase 1
clinical validation
The most promising Mob will be tested for safe use in humans.
OUR LATEST UPDATES
News
Are we prepared for the next pandemic? – Interview
Are we prepared for the next pandemic? EvaMobs researchers Miguel Castanho and Cláudio Soares, along
Kick-off meeting EvaMobs
Strengthening EU’s pandemic preparedness The kick-off of the EvaMobs project What if we could already
WORK WITH US
Job offers
Currently, there are no job offers within the EvaMobs project.
TEAM
Our partners
EvaMobs is a consortium consisting of 11 European partners, coordinated by ITQB NOVA, NOVA University of Lisbon.
OUR RESULTS
Activities and Outputs
Find our communication activities, publications and other outputs.
